Overview

FANTASTIC CLIMATE, EXCELLENT LOCATION

Our Goal:

Ultra low cost production of high quality medical cannabis for the undersupplied domestic Israeli market along with rapid expansion into European markets.

Jurisdiction

As of August 2019, Israel is poised to become the third country behind Canada and Netherlands with an export framework. This opens the door for export into the massive European marketplace.

Domestic Market

+46,000 patients in Israel with an estimated 90,000 anticipated by 2020. Underserved domestic market presents significant and immediate opportunity.

European Market

Germany is our entry point. With the export framework now in place, Isracann aims to become a premier supplier to the European market (pop. over 740 million, double USA and Canada). The EU medical market is estimated to be $64B USD by 2028.

Capital Markets

CSE: IPOT

Isracann Investor Relations

+1 855.205.0226.
inquiries@isracann.com

Company Info

Isracann Biosciences Inc.

Profile

Head Office 1600-595 Burrard Street
Vancouver, BC V7X 1L3
Telephone Number +1 855-205-0226
Fax Number
Business e-mail address inquiries@isracann.com
Stock Symbol CSE: IPOT │ OTC: ISCNF
Auditor MNP LLP
CUSIP Number 46501D 10 8
Financial Year-End May 31
Transfer Agent Computershare Trust Company of Canada
Date of Formation Jan 21 2010
Jurisdiction Where Formed Alberta
Principal Regulator British Columbia
Short Form Prospectus Issuer Yes
Reporting Jurisdictions British Columbia, Alberta, Ontario
Stock Exchange Canadian Securities Exchange (CSE)
Industry Classification Life Sciences
ISIN Number CA 46501D 10 8 7

Share Data

Filings

System for Electronic Document Analysis and Retrieval

Company Profile

Company Filings